Biogen's Rare Disease Drugs Drive Quarter Beat, but Legacy MS Sales Lag
724FinanceEge Kaan
Key Highlights
Biogen, ikinci çeyrek kar ve gelir raporlarını Wall Street beklentilerini aşarak açıkladı. **$2.74 milyar** gelir ve **$3.60** pay başına kar elde ede
Biogen reported second-quarter profit and revenue exceeding Wall Street expectations, with $2.74 billion in revenue and $3.60 per-share earnings. Global sales of its Alzheimer's drug Leqembi rose 15% year-over-year, while legacy MS drugs like Tecfidera saw a 13% decline. The company cut its 2026 forecast to $12-$13 per share due to $3.85 acquisition-related charges from its $5.6 billion Apellis buyout. Markets are watching whether new products and the expanding rare disease portfolio can sustain growth.
Related News & Analysis
View All →Unexpected Fed Rate Hike: How It Could Impact S&P 500 and Air Freight Markets
Accenture CEO Highlights 3 Red Flags Why AI Projects Fail: How Markets React?
Trump Media Stock Surges 48%: Truth API's Impact on Markets
Healthcare Revolution: Alignment Healthcare's Net Profit Doubles
Coca-Cola's Q2 2026 Earnings: Reassessing Consumer Staples Potential
Microsoft's 20-Year Highest Single-Day Gain: Azure and OpenAI Cross $100 Billion Revenue Milestone
Latest Market News
All News →
Ahbap Charity Scandal: Businessman Hüseyin Başaran and 7 Suspects Arrested
Unexpected Fed Rate Hike: How It Could Impact S&P 500 and Air Freight Markets
Accenture CEO Highlights 3 Red Flags Why AI Projects Fail: How Markets React?
Trump Media Stock Surges 48%: Truth API's Impact on Markets